<DOC>
	<DOCNO>NCT02864914</DOCNO>
	<brief_summary>Empagliflozin ( Jardiance ) , highly potent selective inhibitor sodium-glucose cotransporter 2 ( SGLT2 ) , approve Europe May 2014 treatment type 2 diabetes mellitus ( T2DM ) improve glycaemic control adult . As part risk management plan , Boehringer Ingelheim International GmbH ( BI ) commit conduct post-authorisation safety study ( PASS ) evaluate liver renal safety empagliflozin . The study also evaluate risk severe complication urinary tract infection ( UTIs ) genital infection . To evaluate association empagliflozin use mention outcome routinely collect health information Clinical Practice Research Datalink ( CPRD ) , Hospital Episodes Statistics , Office National Statistic use . This PASS conduct observational cohort study among adult patient T2DM least 12 month continuous enrolment CPRD new user empagliflozin compare new user SGLT2 inhibitor new user dipeptidyl peptidase-4 ( DPP4 ) inhibitor . Estimations make crude adjusted incidence rate adjust incidence rate ratio primary secondary outcome . The primary outcome : acute liver injury ( ALI ) , acute kidney injury , hospitalization due severe complication urinary tract infection , genital infection . The secondary outcome : ALI patient without predispose factor , chronic kidney disease , outpatient severe complication UTI , genital infection result hospitalization systemic treatment .</brief_summary>
	<brief_title>PASS Assess Risk Renal Injury , Hepatic Injury , Diabetic Ketoacidosis Infections Empagliflozin-treated Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Patients T2DM , initiate treatment study medication , least 12 month continuous registration CPRD . Exclusion criterion : Patients T1DM , prior use SGLT2 inhibitor DPP4 inhibitor , initiate SGLT2DPP4 fixeddose combination . Additional different exclusion criterion apply accord outcomes interest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>